ID   BC-1
AC   CVCL_1079
SY   BC1
DR   BTO; BTO:0002720
DR   CLO; CLO_0001887
DR   EFO; EFO_0002044
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2230
DR   BioSample; SAMN03471843
DR   BioSample; SAMN03473432
DR   BioSamples; SAMEA365796
DR   BioSamples; SAMEA365808
DR   cancercelllines; CVCL_1079
DR   Cell_Model_Passport; SIDM00896
DR   ChEMBL-Cells; CHEMBL3307907
DR   ChEMBL-Targets; CHEMBL614277
DR   Cosmic; 687602
DR   Cosmic; 910919
DR   Cosmic; 1515186
DR   Cosmic; 1588556
DR   Cosmic-CLP; 910919
DR   DepMap; ACH-002214
DR   DSMZ; ACC-677
DR   DSMZCellDive; ACC-677
DR   EGA; EGAS00001000978
DR   GDSC; 910919
DR   GEO; GSM33136
DR   GEO; GSM38792
DR   GEO; GSM38793
DR   GEO; GSM634731
DR   GEO; GSM710417
DR   GEO; GSM710433
DR   GEO; GSM1669610
DR   GEO; GSM3150236
DR   IARC_TP53; 21189
DR   IARC_TP53; 23656
DR   IGRhCellID; BC1
DR   LINCS_LDP; LCL-1956
DR   Lonza; 914
DR   PharmacoDB; BC1_77_2019
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1079
DR   PubChem_Cell_line; CVCL_1079
DR   Wikidata; Q54795185
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   Patent=US5908773;
RX   PubMed=7670109;
RX   PubMed=8523568;
RX   PubMed=9766492;
RX   PubMed=15613351;
RX   PubMed=17121789;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21685375;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
RX   PubMed=36094314;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=BC-1
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~35-48 hours (DSMZ=ACC-677).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: Array-based CGH.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.64%; East Asian, North=0.52%; East Asian, South=0%; South Asian=0.4%; European, North=67.92%; European, South=30.53% (PubMed=30894373).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8
ST   D16S539: 12,13
ST   D18S51: 12,15
ST   D19S433: 13,14
ST   D21S11: 28,30
ST   D2S1338: 19,23
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 14,16
ST   FGA: 22,23
ST   Penta D: 11
ST   Penta E: 11,12
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 16,20
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_4221 ! HBL-6
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 39
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   Patent=US5908773;
RA   Cesarman E., Arvanitakis L., Knowles D.M., Mesri E.A.;
RT   "KSHV positive cell lines.";
RL   Patent number US5908773, 01-Jun-1999.
//
RX   PubMed=7670109; DOI=10.1182/blood.V86.7.2708.2708;
RA   Cesarman E., Moore P.S., Rao P.H., Inghirami G., Knowles D.M.,
RA   Chang Y.;
RT   "In vitro establishment and characterization of two acquired
RT   immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2)
RT   containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA
RT   sequences.";
RL   Blood 86:2708-2714(1995).
//
RX   PubMed=8523568; DOI=10.1128/JVI.70.1.549-558.1996;
RA   Moore P.S., Gao S.-J., Dominguez G., Cesarman E., Lungu O.,
RA   Knowles D.M., Garber R., Pellett P.E., McGeoch D.J., Chang Y.;
RT   "Primary characterization of a herpesvirus agent associated with
RT   Kaposi's sarcomae.";
RL   J. Virol. 70:549-558(1996).
//
RX   PubMed=9766492; DOI=10.1038/sj.leu.2401160;
RA   Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.;
RT   "Lymphoma cell lines: in vitro models for the study of HHV-8+ primary
RT   effusion lymphomas (body cavity-based lymphomas).";
RL   Leukemia 12:1507-1517(1998).
//
RX   PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005;
RA   Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E.,
RA   Knowles D.M.;
RT   "Distinct subsets of primary effusion lymphoma can be identified based
RT   on their cellular gene expression profile and viral association.";
RL   J. Virol. 79:1244-1251(2005).
//
RX   PubMed=17121789; DOI=10.1128/JVI.01757-06;
RA   Burd C.E., Sin S.-H., Dittmer D.P.;
RT   "Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus
RT   lymphomas: implications for therapy.";
RL   J. Virol. 81:1912-1922(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=36094314; DOI=10.1128/JVI.00739-22;
RA   Ding W.-Y., Wang C., Narita Y., Wang H.-B., Leong M.M.L., Huang A.,
RA   Liao Y.-F., Liu X.-F., Okuno Y., Kimura H., Gewurz B.E., Teng M.-X.,
RA   Jin S.-L., Sato Y., Zhao B.;
RT   "The Epstein-Barr virus enhancer interaction landscapes in
RT   virus-associated cancer cell lines.";
RL   J. Virol. 96:e0073922.1-e0073922.11(2022).
//